Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

Decision-making under uncertainty: comparing regulatory and health technology assessment reviews of medicines in the US and Europe.

Vreman RA, Naci H, Goettsch WG, Mantel-Teeuwisse AK, Schneeweiss SG, Leufkens HG, Kesselheim AS.

Clin Pharmacol Ther. 2020 Apr 1. doi: 10.1002/cpt.1835. [Epub ahead of print]

PMID:
32236959
2.

Generating comparative evidence on new drugs and devices after approval.

Cipriani A, Ioannidis JPA, Rothwell PM, Glasziou P, Li T, Hernandez AF, Tomlinson A, Simes J, Naci H.

Lancet. 2020 Mar 21;395(10228):998-1010. doi: 10.1016/S0140-6736(19)33177-0. Review.

PMID:
32199487
3.

Generating comparative evidence on new drugs and devices before approval.

Naci H, Salcher-Konrad M, Kesselheim AS, Wieseler B, Rochaix L, Redberg RF, Salanti G, Jackson E, Garner S, Stroup TS, Cipriani A.

Lancet. 2020 Mar 21;395(10228):986-997. doi: 10.1016/S0140-6736(19)33178-2. Review.

PMID:
32199486
4.

Ethical implications of poor comparative effectiveness evidence: obligations in industry-research partnerships.

Singh I, Naci H, Miller J, Caplan A, Cipriani A.

Lancet. 2020 Mar 21;395(10228):926-928. doi: 10.1016/S0140-6736(20)30413-X. No abstract available.

PMID:
32199476
5.

Association Between the Use of Surrogate Measures in Pivotal Trials and Health Technology Assessment Decisions: A Retrospective Analysis of NICE and CADTH Reviews of Cancer Drugs.

Pinto A, Naci H, Neez E, Mossialos E.

Value Health. 2020 Mar;23(3):319-327. doi: 10.1016/j.jval.2019.10.010. Epub 2020 Jan 13.

PMID:
32197727
6.

Inappropriate use of progression-free survival in cancer drug approvals.

Naci H, Davis C.

BMJ. 2020 Mar 10;368:m770. doi: 10.1136/bmj.m770. No abstract available.

PMID:
32156802
7.

The Supercar Stays in the Garage: Factors Preventing Indirect Comparisons of Novel Medicines Targeting the Same Condition.

Ollendorf DA, Kim E, Bridger N, Naci H.

J Manag Care Spec Pharm. 2020 Mar;26(3):333-334. doi: 10.18553/jmcp.2020.26.3.333.

8.

Prognostic Significance of Left Ventricular Noncompaction: Systematic Review and Meta-Analysis of Observational Studies.

Aung N, Doimo S, Ricci F, Sanghvi MM, Pedrosa C, Woodbridge SP, Al-Balah A, Zemrak F, Khanji MY, Munroe PB, Naci H, Petersen SE.

Circ Cardiovasc Imaging. 2020 Jan;13(1):e009712. doi: 10.1161/CIRCIMAGING.119.009712. Epub 2020 Jan 21.

9.

Infographic. How does exercise treatment compare with antihypertensive medications?

Castillo-Garcia A, Naci H, Valenzuela PL, Salcher-Konrad M, Dias S, Blum MR, Sahoo SA, Nunan D, Morales JS, Lucia A, Ioannidis JP.

Br J Sports Med. 2019 Dec 19. pii: bjsports-2019-101522. doi: 10.1136/bjsports-2019-101522. [Epub ahead of print] No abstract available.

PMID:
31857338
10.

Comparative fertility and pregnancy outcomes after local treatment for cervical intraepithelial neoplasia and stage 1a1 cervical cancer: protocol for a systematic review and network meta-analysis from the CIRCLE group.

Athanasiou A, Veroniki AA, Efthimiou O, Kalliala I, Naci H, Bowden S, Paraskevaidi M, Martin-Hirsch P, Bennett P, Paraskevaidis E, Salanti G, Kyrgiou M.

BMJ Open. 2019 Oct 21;9(10):e028009. doi: 10.1136/bmjopen-2018-028009.

11.

European Medicines Agency's Priority Medicines Scheme at 2 Years: An Evaluation of Clinical Studies Supporting Eligible Drugs.

Neez E, Hwang TJ, Sahoo SA, Naci H.

Clin Pharmacol Ther. 2020 Mar;107(3):541-552. doi: 10.1002/cpt.1669. Epub 2019 Nov 22.

PMID:
31591708
12.

Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis.

Naci H, Davis C, Savović J, Higgins JPT, Sterne JAC, Gyawali B, Romo-Sandoval X, Handley N, Booth CM.

BMJ. 2019 Sep 18;366:l5221. doi: 10.1136/bmj.l5221.

13.

Comparative efficacy and complication rates after local treatment for cervical intraepithelial neoplasia and stage 1a1 cervical cancer: protocol for a systematic review and network meta-analysis from the CIRCLE Group.

Athanasiou A, Veroniki AA, Efthimiou O, Kalliala I, Naci H, Bowden S, Paraskevaidi M, Martin-Hirsch P, Bennett P, Paraskevaidis E, Salanti G, Kyrgiou M.

BMJ Open. 2019 Aug 2;9(8):e028008. doi: 10.1136/bmjopen-2018-028008.

14.

Relative Efficacy of Spironolactone, Eplerenone, and cAnRenone in patients with Chronic Heart failure (RESEARCH): a systematic review and network meta-analysis of randomized controlled trials.

Frankenstein L, Seide S, Täger T, Jensen K, Fröhlich H, Clark AL, Seiz M, Katus HA, Nee P, Uhlmann L, Naci H, Atar D.

Heart Fail Rev. 2020 Mar;25(2):161-171. doi: 10.1007/s10741-019-09832-y. Review.

PMID:
31364027
15.

Impact of predictive medicine on therapeutic decision making: a randomized controlled trial in congenital heart disease.

Naci H, Salcher-Konrad M, Mcguire A, Berger F, Kuehne T, Goubergrits L, Muthurangu V, Wilson B, Kelm M.

NPJ Digit Med. 2019 Mar 19;2:17. doi: 10.1038/s41746-019-0085-1. eCollection 2019.

16.

Effectiveness of interventions for dementia in low- and middle-income countries: protocol for a systematic review, pairwise and network meta-analysis.

Salcher-Konrad M, Naci H, McDaid D, Alladi S, Oliveira D, Fry A, Hussein S, Knapp M, Musyimi CW, Ndetei DM, Lopez-Ortega M, Comas-Herrera A.

BMJ Open. 2019 Jun 19;9(6):e027851. doi: 10.1136/bmjopen-2018-027851.

17.

A Cost-Utility Analysis of Cryoballoon Ablation versus Radiofrequency Ablation for Paroxysmal Atrial Fibrillation.

Murray MI, Bonet MJ, Naci H, Zeiher AM.

J Atr Fibrillation. 2018 Dec 31;11(4):2069. doi: 10.4022/jafib.2069. eCollection 2018 Dec.

18.

Cyprus Women's Health Research (COHERE) initiative: determining the relative burden of women's health conditions and related co-morbidities in an Eastern Mediterranean population.

Hocaoglu MB, Gurkas S, Karaderi T, Taneri B, Erguler K, Barin B, Bilgin EM, Eralp G, Allison M, Findikli N, Boynukalin K, Bahceci M, Naci H, Vincent K, Missmer SA, Becker CM, Zondervan KT, Rahmioglu N.

BMC Womens Health. 2019 Apr 3;19(1):50. doi: 10.1186/s12905-019-0750-1. No abstract available.

19.

Combining Multiple Treatment Comparisons with Personalized Patient Preferences: A Randomized Trial of an Interactive Platform for Statin Treatment Selection.

Hopkin G, Au A, Collier VJ, Yudkin JS, Basu S, Naci H.

Med Decis Making. 2019 Apr;39(3):264-277. doi: 10.1177/0272989X19835239. Epub 2019 Mar 15.

PMID:
30873906
20.

Personalizing Second-Line Type 2 Diabetes Treatment Selection: Combining Network Meta-analysis, Individualized Risk, and Patient Preferences for Unified Decision Support.

Choi SE, Berkowitz SA, Yudkin JS, Naci H, Basu S.

Med Decis Making. 2019 Apr;39(3):239-252. doi: 10.1177/0272989X19829735. Epub 2019 Feb 15.

21.

New agreement on branded drugs for the NHS.

Naci H, Dixon J.

BMJ. 2019 Jan 18;364:l266. doi: 10.1136/bmj.l266. No abstract available.

PMID:
30658964
22.

How does exercise treatment compare with antihypertensive medications? A network meta-analysis of 391 randomised controlled trials assessing exercise and medication effects on systolic blood pressure.

Naci H, Salcher-Konrad M, Dias S, Blum MR, Sahoo SA, Nunan D, Ioannidis JPA.

Br J Sports Med. 2019 Jul;53(14):859-869. doi: 10.1136/bjsports-2018-099921. Epub 2018 Dec 18.

PMID:
30563873
23.

Assessment of Devices, Diagnostics and Digital Technologies: A Review of NICE Medical Technologies Guidance.

Crispi F, Naci H, Barkauskaite E, Osipenko L, Mossialos E.

Appl Health Econ Health Policy. 2019 Apr;17(2):189-211. doi: 10.1007/s40258-018-0438-y.

PMID:
30367349
24.

A review of NICE appraisals of pharmaceuticals 2000-2016 found variation in establishing comparative clinical effectiveness.

Anderson M, Naci H, Morrison D, Osipenko L, Mossialos E.

J Clin Epidemiol. 2019 Jan;105:50-59. doi: 10.1016/j.jclinepi.2018.09.003. Epub 2018 Sep 18. Review.

PMID:
30236484
25.

Planning a future randomized clinical trial based on a network of relevant past trials.

Salanti G, Nikolakopoulou A, Sutton AJ, Reichenbach S, Trelle S, Naci H, Egger M.

Trials. 2018 Jul 11;19(1):365. doi: 10.1186/s13063-018-2740-2.

26.

The US Food and Drug Administration's expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements.

Wallach JD, Ross JS, Naci H.

Clin Trials. 2018 Jun;15(3):219-229. doi: 10.1177/1740774518770648.

PMID:
29871509
27.

The US Food and Drug Administration's expedited approval programs: Addressing premarket flexibility with enhanced postmarket evidence generation.

Wallach JD, Ross JS, Naci H.

Clin Trials. 2018 Jun;15(3):243-246. doi: 10.1177/1740774518770657. No abstract available.

PMID:
29871507
28.

Evidence Required for Drugs Granted Accelerated Approval-Reply.

Naci H, Kesselheim AS.

JAMA. 2017 Dec 26;318(24):2493-2494. doi: 10.1001/jama.2017.17184. No abstract available.

PMID:
29279923
29.

Training the next generation of cardiovascular leaders in health policy and economics.

Naci H, Kirchhof P, Vahanian A, Steffel J, Bardinet I, Mossialos E, Vardas P.

Eur Heart J. 2017 Dec 1;38(45):3332-3335. doi: 10.1093/eurheartj/ehx673. No abstract available.

PMID:
29206965
30.

Accelerated access to new drugs and technologies.

Naci H, Mossialos E.

BMJ. 2017 Nov 22;359:j5387. doi: 10.1136/bmj.j5387. No abstract available.

PMID:
29167095
31.
32.

Evolocumab in Patients with Cardiovascular Disease.

Naci H, Mehra MR.

N Engl J Med. 2017 Aug 24;377(8):785-6. doi: 10.1056/NEJMc1708587. No abstract available.

PMID:
28836419
33.

Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration.

Naci H, Smalley KR, Kesselheim AS.

JAMA. 2017 Aug 15;318(7):626-636. doi: 10.1001/jama.2017.9415.

34.

Health policy in times of austerity-A conceptual framework for evaluating effects of policy on efficiency and equity illustrated with examples from Europe since 2008.

Wenzl M, Naci H, Mossialos E.

Health Policy. 2017 Sep;121(9):947-954. doi: 10.1016/j.healthpol.2017.07.005. Epub 2017 Jul 19.

35.

Impact of the International Recommendations for Electrocardiographic Interpretation on Cardiovascular Screening in Young Athletes.

Dhutia H, Malhotra A, Finocchiaro G, Merghani A, Papadakis M, Naci H, Tome M, Sharma S.

J Am Coll Cardiol. 2017 Aug 8;70(6):805-807. doi: 10.1016/j.jacc.2017.06.018. No abstract available.

36.

What to do (or not to do) when randomization is not possible.

Naci H.

J Heart Lung Transplant. 2017 Nov;36(11):1174-1177. doi: 10.1016/j.healun.2017.07.008. Epub 2017 Jul 17. No abstract available.

PMID:
28756119
37.

Timing and Characteristics of Cumulative Evidence Available on Novel Therapeutic Agents Receiving Food and Drug Administration Accelerated Approval.

Naci H, Wouters OJ, Gupta R, Ioannidis JPA.

Milbank Q. 2017 Jun;95(2):261-290. doi: 10.1111/1468-0009.12261.

38.

Avoidable costs of stenting for aortic coarctation in the United Kingdom: an economic model.

Salcher M, Mcguire A, Muthurangu V, Kelm M, Kuehne T, Naci H; CARDIOPROOF.

BMC Health Serv Res. 2017 Apr 10;17(1):258. doi: 10.1186/s12913-017-2215-2.

39.

The impact of post-procedural complications on reimbursement, length of stay and mechanical ventilation among patients undergoing transcatheter aortic valve implantation in Germany.

Kaier K, Reinecke H, Naci H, Frankenstein L, Bode M, Vach W, Hehn P, Zirlik A, Zehender M, Reinöhl J.

Eur J Health Econ. 2018 Mar;19(2):223-228. doi: 10.1007/s10198-017-0877-7. Epub 2017 Feb 22.

PMID:
28229254
40.

Bicuspid aortic valve disease: systematic review and meta-analysis of surgical aortic valve repair.

Salcher M, Naci H, Pender S, Kuehne T; CARDIOPROOF Consortium, Kelm M.

Open Heart. 2016 Dec 16;3(2):e000502. doi: 10.1136/openhrt-2016-000502. eCollection 2016.

41.

Communication of Treatment Rankings Obtained From Network Meta-Analysis Using Data Visualization.

Naci H.

Circ Cardiovasc Qual Outcomes. 2016 Sep;9(5):605-8. doi: 10.1161/CIRCOUTCOMES.116.002874. Epub 2016 Sep 6. No abstract available.

PMID:
27601459
42.

Cost Implications of Using Different ECG Criteria for Screening Young Athletes in the United Kingdom.

Dhutia H, Malhotra A, Gabus V, Merghani A, Finocchiaro G, Millar L, Narain R, Papadakis M, Naci H, Tome M, Sharma S.

J Am Coll Cardiol. 2016 Aug 16;68(7):702-11. doi: 10.1016/j.jacc.2016.05.076.

43.

History Bias, Study Design, and the Unfulfilled Promise of Pay-for-Performance Policies in Health Care.

Naci H, Soumerai SB.

Prev Chronic Dis. 2016 Jun 23;13:E82. doi: 10.5888/pcd13.160133. No abstract available.

44.

Balloon Dilatation and Stenting for Aortic Coarctation: A Systematic Review and Meta-Analysis.

Salcher M, Naci H, Law TJ, Kuehne T, Schubert S, Kelm M; Cardioproof Consortium.

Circ Cardiovasc Interv. 2016 Jun;9(6). pii: e003153. doi: 10.1161/CIRCINTERVENTIONS.115.003153. Review.

PMID:
27296199
45.

Economic evaluation of mental health interventions: an introduction to cost-utility analysis.

Luyten J, Naci H, Knapp M.

Evid Based Ment Health. 2016 May;19(2):49-53. doi: 10.1136/eb-2016-102354. Epub 2016 Apr 13. Review.

PMID:
27075444
46.

Preventing cardiovascular events with empagliflozin: at what cost?

Naci H, Basu S, Yudkin JS.

Lancet Diabetes Endocrinol. 2015 Dec;3(12):931. doi: 10.1016/S2213-8587(15)00439-8. No abstract available.

PMID:
26590682
47.

Timely publication and sharing of trial data: opportunities and challenges for comparative effectiveness research in cardiovascular disease.

Naci H, Cooper J, Mossialos E.

Eur Heart J Qual Care Clin Outcomes. 2015 Nov 1;1(2):58-65. doi: 10.1093/ehjqcco/qcv012.

PMID:
29474595
48.

Why the drug development pipeline is not delivering better medicines.

Naci H, Carter AW, Mossialos E.

BMJ. 2015 Oct 23;351:h5542. doi: 10.1136/bmj.h5542. No abstract available.

49.

Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study.

Naci H, Ioannidis JP.

Br J Sports Med. 2015 Nov;49(21):1414-22. doi: 10.1136/bjsports-2015-f5577rep. Review.

50.

Rethinking the appraisal and approval of drugs for type 2 diabetes.

Naci H, Lehman R, Wouters OJ, Goldacre B, Yudkin JS.

BMJ. 2015 Oct 9;351:h5260. doi: 10.1136/bmj.h5260. Review. No abstract available.

PMID:
26452524

Supplemental Content

Support Center